ERJ Open Research最新文献

{"title":"Utility of adding oesophageal to endobronchial endosonography when staging lung cancer: a randomised trial.","authors":"Masahide Oki, Hideo Saka, Yukio Seki, Yoshihito Kogure, Hideyuki Niwa, Arisa Yamada, Atsushi Torii, Chiyoe Kitagawa, Masahiko Ando","doi":"10.1183/23120541.00326-2024","DOIUrl":"https://doi.org/10.1183/23120541.00326-2024","url":null,"abstract":"<p><strong>Introduction: </strong>Both combined endobronchial ultrasonography (EBUS) and transoesophageal bronchoscopic ultrasonography (EUS-B) and EBUS alone have been recommended for preoperative mediastinal staging of nonsmall cell lung cancer (NSCLC). However, no randomised study comparing these two methods has been published. The purpose of the present study was to compare the sensitivity of EBUS and that of combined EBUS and EUS-B (EBUS/EUS-B) in terms of detecting N2/N3 disease during staging of NSCLC.</p><p><strong>Methods: </strong>Patients with known or suspected, potentially operable NSCLC were recruited and randomised to undergo EBUS or EBUS/EUS-B under conscious sedation. The primary end-point was a comparison of the sensitivity of EBUS alone and EBUS/EUS-B.</p><p><strong>Results: </strong>A total of 240 patients were enrolled and randomised, among whom 219 (105 EBUS group; 114 EBUS/EUS-B group) were included in the analysis. The sensitivities of EBUS and EBUS/EUS-B in terms of detecting N2/N3 disease were 75.0% and 79.3% respectively (p=0.698). In the EBUS/EUS-B group, only EUS-B yielded diagnostic results in two patients; the sensitivity thus increased from 72.4% to 79.3% on addition of EUS-B to EBUS.</p><p><strong>Conclusions: </strong>The difference in the sensitivities of EBUS alone and EBUS/EUS-B in terms of diagnosing N2/N3 disease was not statistically significant. Although the increase in sensitivity with the addition of EUS-B is modest, it is maximised when EUS-B is used to sample lymph nodes not accessible by EBUS alone.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An exploration of clinically meaningful definitions of cough bouts.","authors":"Kimberley J Holt, Rachel J Dockry, Kevin McGuinness, Emma Barrett, Jaclyn A Smith","doi":"10.1183/23120541.00316-2024","DOIUrl":"https://doi.org/10.1183/23120541.00316-2024","url":null,"abstract":"<p><strong>Rationale: </strong>The measurement of cough frequency is widely used in clinical trials, typically expressed as the number of explosive cough sounds per hour. However, this measure does not capture the clustering of coughs into bouts. Coughing bouts contribute to perceived cough severity and the physical complications of coughing, but an agreed standard definition of cough bouts is lacking. The objectives of the present study were to explore the impact of different definitions of cough bouts on the parameters generated, their relationships with reported cough severity and influence of age and gender in refractory chronic cough (RCC).</p><p><strong>Methods: </strong>We analysed 24-h acoustic recordings and concurrent cough severity visual analogue scales from 91 RCC patients (62% female, median (interquartile range) age 60.0 (54-67.0) years). A custom-built algorithm calculated cough bouts, defined by the intervals between explosive cough sounds. Bouts defined by inter-cough intervals from ≤0.5 to ≤10 s (0.5 s increments) were explored, and parameters including number of bouts, median/maximum bout length and total bout duration calculated.</p><p><strong>Measurements and main results: </strong>Using inter-cough intervals of >3 s to define cough bouts made little difference to cough bout parameters. Correlations between cough severity and bout parameters were weak but most likely to be significant when single coughs were removed. Cough-free time/total time spent coughing tended to have more influence on cough severity than the average cough bout length, irrespective of the interval used.</p><p><strong>Conclusion: </strong>These analyses favour definitions of cough bouts utilising inter-cough intervals of ≤3 s and the exclusion of single coughs from cough bout analysis.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11610081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Driving restrictions in patients with obstructive sleep apnoea: who, how and are they effective?","authors":"Walter T McNicholas","doi":"10.1183/23120541.00634-2024","DOIUrl":"https://doi.org/10.1183/23120541.00634-2024","url":null,"abstract":"<p><p><b>Effective treatment of OSA reduces driving accident risk</b> https://bit.ly/3zzQUEN.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11610064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers troponin and procalcitonin in addition to CRB-65 enhance risk stratification in patients with community-acquired pneumonia.","authors":"Imrana Farhat, Maciej Rosolowski, Katharina Ahrens, Jasmin Lienau, Peter Ahnert, Mathias Pletz, Gernot Rohde, Jan Rupp, Markus Scholz, Martin Witzenrath","doi":"10.1183/23120541.00420-2024","DOIUrl":"https://doi.org/10.1183/23120541.00420-2024","url":null,"abstract":"<p><strong>Background: </strong>Community-acquired pneumonia (CAP) remains a leading cause of infectious disease mortality globally, necessitating intensive care unit (ICU) admission for ∼10% of hospitalised patients. Accurate prediction of disease severity facilitates timely therapeutic interventions.</p><p><strong>Methods: </strong>Our study aimed to enhance the predictive capacity of the clinical CRB-65 score by evaluating eight candidate biomarkers: troponin T high-sensitive (TnT-hs), procalcitonin (PCT), N-terminal pro-brain natriuretic peptide, angiopoietin-2, copeptin, endothelin-1, lipocalin-2 and mid-regional pro-adrenomedullin. We utilised a machine-learning approach on 800 samples from the German CAPNETZ network (competence network for CAP) to refine risk prediction models combining these biomarkers with the CRB-65 score regarding our defined end-point: death or ICU admission during the current CAP episode within 28 days after study inclusion.</p><p><strong>Results: </strong>Elevated levels of biomarkers were associated with the end-point. TnT-hs exhibited the highest predictive performance among individual features (area under the receiver operating characteristic curve, AUC=0.74), followed closely by PCT (AUC=0.73). Combining biomarkers with the CRB-65 score significantly improved prediction accuracy. The combined model of CRB-65, TnT-hs and PCT demonstrated the best balance between high predictive value and parsimony, with an AUC of 0.77 (95% CI: 0.72-0.82), while CRB-65 alone achieved an AUC of 0.67 (95% CI: 0.64-0.73).</p><p><strong>Conclusion: </strong>Our findings suggest that augmenting the CRB-65 score with TnT-hs and PCT enhances the prediction of death or ICU admission in hospitalised CAP patients. Validation of this improved risk score in additional CAP cohorts and prospective clinical studies is warranted to assess its broad clinical utility.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of efficacy of tocilizumab in acute exacerbation of pulmonary fibrosis.","authors":"Giovanni Franco, Pierre Le Guen, Mathilde Le Brun, Quentin Philippot, Clairelyne Dupin, Marie-Pierre Debray, Catherine Bancal, Camille Taillé, Raphaël Borie, Bruno Crestani","doi":"10.1183/23120541.00520-2024","DOIUrl":"https://doi.org/10.1183/23120541.00520-2024","url":null,"abstract":"<p><p><b>Given the high mortality rate observed in our data, tocilizumab is not recommended as a salvage therapy for patients affected by acute exacerbation of pulmonary fibrosis who did not show clinical improvement after three steroids bolus</b> https://bit.ly/3ClggYb.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11610078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achieving adherence to positive airway pressure in commercial drivers using an employer-mandated remote management programme.","authors":"Elizabeth Kneeland, Nadia Ali, David G Maislin, Yoon Hee Chang, Joyce Epelboim, Brendan T Keenan, Allan I Pack","doi":"10.1183/23120541.00132-2024","DOIUrl":"10.1183/23120541.00132-2024","url":null,"abstract":"<p><strong>Background: </strong>Obstructive sleep apnoea (OSA) is common in commercial drivers, and associated with increased risk of crashes if untreated, making diagnosis and effective treatment crucial in this population.</p><p><strong>Study design and methods: </strong>This is a retrospective summary of a clinical programme based on telemedicine and remote treatment monitoring developed with a national trucking company to screen new hires in the USA for OSA and implement positive airway pressure (PAP) management. New hires were informed of the programme and consented as part of their employment. Drivers who did not comply with the evaluation or with PAP after diagnosis were removed from driving commercial vehicles by the company or did not pursue further employment.</p><p><strong>Results: </strong>A total of 975 drivers were enrolled. Among screened drivers, 35.5% were cleared without a sleep study, 15.0% were cleared following a sleep study (apnoea-hypopnoea index (AHI) <5 events·h^-1), 22.1% had mild OSA (AHI 5-15) and 27.4% had moderate-severe OSA (AHI ≥15). Those with moderate-severe OSA were more obese (body mass index 36.2±6.3 kg·m^-2) and had more comorbidities. Of 269 drivers starting PAP, 160 (59.5%) maintained participation in a care management programme, 80 (29.7%) resigned or were terminated, 23 (8.6%) were cleared to discontinue PAP and six (2.2%) were complex cases requiring transfer of care. Illustrating effectiveness, those that maintained participation had excellent PAP adherence (5.27±1.61 h·night^-1; 88.5±12.9% days used; 79.7±17.7% days used ≥4 h).</p><p><strong>Interpretation: </strong>Remote assessment of OSA and PAP management in commercial drivers is feasible and effective. This approach has wide-ranging applications, particularly in populations and areas with a lack of sleep medicine providers.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11610067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vasoreactivity and inhaled treprostinil response in interstitial lung disease pulmonary hypertension.","authors":"Eileen M Harder, Farbod N Rahaghi, Jane A Leopold, David M Systrom, George R Washko, Aaron B Waxman","doi":"10.1183/23120541.00201-2024","DOIUrl":"https://doi.org/10.1183/23120541.00201-2024","url":null,"abstract":"<p><strong>Introduction: </strong>Despite shared features with pulmonary arterial hypertension, acute vasoreactivity in pulmonary hypertension with interstitial lung disease (PH-ILD) is not well characterised, including its potential ability to predict therapeutic outcomes. We sought to determine whether acute vasoreactivity in PH-ILD to oxygen (O₂) and inhaled nitric oxide (iNO) predicts inhaled treprostinil (iTre) outcomes.</p><p><strong>Materials and methods: </strong>In this retrospective cohort analysis, we identified treatment-naive PH-ILD patients with vasoreactivity testing using O₂ and O₂+iNO. 6-month iTre outcome was assessed. \"iTre improvement\" required fulfilment of criteria on objective assessment without clinical worsening. \"iTre failure\" was defined by lack of objective improvement or a clinical worsening event.</p><p><strong>Results: </strong>Among 75 PH-ILD patients, mean pulmonary arterial pressure (mPAP) decreased by -3 mmHg (-12.6%) and pulmonary vascular resistance (PVR) by -1.3 WU (-23.7%) with O₂+iNO. With O₂+iNO, mPAP decreased ≥10 mmHg to <40 mmHg in four patients (5.3%) and 23 (30.7%) had ≥20% reduction in mPAP and PVR. Among 33 iTre-treated patients, there were 13 improvements and 20 failures. The microvascular response, measured by distensibility, to O₂ alone <i>versus</i> O₂+iNO correlated with 6-month iTre outcome. Patients with 6-month iTre improvement had large relative distensibility increases with O₂+iNO (<i>versus</i> failure, 76.0% <i>versus</i> 15.3%, p=0.004). Conversely, iTre failure was associated with increased distensibility with O₂ alone (<i>versus</i> improvement, 26.8% <i>versus</i> -3.9%, p=0.045).</p><p><strong>Conclusions: </strong>In PH-ILD, the microvascular response to O₂ <i>versus</i> O₂+iNO testing was associated with 6-month iTre outcome, likely reflecting the differential contributions of hypoxic vasoconstriction and remodelling. Acute vasoreactivity may inform therapeutic decision-making in PH-ILD.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial.","authors":"Lina Brinkmann, Jan Fuge, Tobias Welte, Hendrik Suhling, Nora Drick","doi":"10.1183/23120541.00374-2024","DOIUrl":"10.1183/23120541.00374-2024","url":null,"abstract":"<p><strong>Background: </strong>Severe asthma affects the working life of millions of people worldwide. Interleukin (IL)-5/anti-interleukin-5 receptor α (IL-5Rα) antibodies are highly effective in reducing symptoms in patients with severe eosinophilic asthma. We analysed effects of anti-IL-5/anti-IL-5Rα treatment on self-reported productivity and absenteeism at work in patients with severe eosinophilic asthma.</p><p><strong>Methods: </strong>In this prospective single-centre study, patients with severe eosinophilic asthma received a questionnaire assessing their actual occupational status and the influence asthma has on their work life, productivity and missed days at work prior to initiation of antibody treatment and after 6 and 12 months of therapy. Among others, the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) was used.</p><p><strong>Results: </strong>Out of 54 patients with a median age of 60 years, 27 (50%) were employed. In addition to an increase in asthma control and lung function, self-reported productivity increased significantly with a decrease on the WPAI:SHP from 30% (interquartile range (IQR) 20-50%) to 10% (IQR 0-27.5%) under treatment (p=0.001). Furthermore, self-reported missed days at work were reduced from 2 days·month^-1 (IQR 1.75-6 days·month^-1) to 0 days·month^-1 (IQR 0-2 days·month^-1; p=0.067). At baseline 22 employed patients (81%) stated they were affected at work by their asthma. After 12 months of treatment, this number decreased to eight patients (30%; p=0.038).</p><p><strong>Conclusions: </strong>This prospective analysis could prove the substantial impact severe asthma has on patients' working life. Anti-IL-5/anti-IL-5Rα treatment in patients with severe eosinophilic asthma leads to a significant increase in self-reported productivity at work, and after 12 months of treatment patients state substantially fewer negative effects on their working situation.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Canadian Bronchiectasis and Nontuberculous Mycobacteria Registry: a study protocol.","authors":"Christina S Thornton, Nicole Boechler, Vidhi Desai, Ranjani Somayaji, Swathi Purighalla, Sarah Brode, Theodore K Marras, Ryan Cooper, Maeve Smith, Julie Jarand","doi":"10.1183/23120541.00412-2024","DOIUrl":"10.1183/23120541.00412-2024","url":null,"abstract":"<p><strong>Background: </strong>Bronchiectasis is a complex, chronic disease with geographic and ethnic diversity. While the most substantial cohort studies have been conducted in Europe and the USA, Canada also faces considerable challenges. The comprehensive Canadian Bronchiectasis and Nontuberculous Mycobacterial (NTM) Registry aims to 1) outline the clinical characteristics and natural history of bronchiectasis in Canada, 2) identify risk factors contributing to disease progression within Canadians, 3) integrate comprehensive clinical information to better understand the phenotypes of bronchiectasis and 4) support the development of large-scale, randomised controlled trials in Canada.</p><p><strong>Methods: </strong>The Canadian Bronchiectasis and NTM Registry is an ongoing prospective, longitudinal, multi-centre, observational cohort study. It aims to enrol at least 2000 participants to collect data such as medical history, aetiological assessments, lung function tests, microbiological profiles, radiographic evaluations, comorbidities and quality of life (QoL) metrics. Participants will undergo annual follow-ups to gather longitudinal information regarding outcomes, treatments and changes in QoL. The inclusion criteria are a diagnosis of bronchiectasis by clinical history and computed tomography and/or pulmonary NTM infection as defined by American Thoracic Society/Infectious Diseases Society of America guidelines. The study's protocol received ethical approval from the lead site, the University of Calgary, with future additional approval from local ethics committees at all participating centres.</p><p><strong>Discussion: </strong>The outcomes of the registry will be instrumental in uncovering the clinical traits and natural history of bronchiectasis. This longitudinal study will be used for analysis to form evidence-based clinical practices and serve as a resource in Canada to inform future studies in NTM and bronchiectasis.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of expiratory flow limitation on supine persistent hyperinflation in COPD: a prospective observational study.","authors":"Meera Srinivasan, Hannah Pollard, David G Chapman, Katrina Tonga, Kieran Patel, Kaj Blokland, David Touma, Cindy Thamrin, Troy Cross, Kim Prisk, Gregory G King","doi":"10.1183/23120541.00255-2024","DOIUrl":"10.1183/23120541.00255-2024","url":null,"abstract":"<p><strong>Introduction: </strong>COPD is characterised by airflow obstruction, expiratory airway collapse and closure causing expiratory flow limitation (EFL) and hyperinflation. Supine posture may worsen ventilatory function in COPD, which may cause hyperinflation to persist and contribute to symptoms of orthopnoea and sleep disturbance. Our aim was to determine the impact of supine posture on hyperinflation, dynamic elastance and EFL in COPD and healthy subjects. We hypothesised that changes in hyperinflation in supine posture are influenced by EFL and gas trapping in COPD.</p><p><strong>Methods: </strong>Clinically stable COPD patients (compatible symptoms, smoking >10 pack-years, obstructed spirometry) and healthy controls underwent oscillometry in the seated and supine positions. Hyperinflation was measured by inspiratory capacity (IC) and the ratio of IC to total lung capacity (IC/TLC) while seated and supine EFL was measured as the difference in mean inspiratory and mean expiratory oscillatory reactance at 5 Hz (<i>X</i> _rs5). Relationships between IC, IC/TLC and <i>X</i> _rs5, were examined by Spearman correlation.</p><p><strong>Results: </strong>42 COPD patients demonstrated no change in IC/TLC from seated (0.31 L) to supine (0.32 L) position (p=0.079) compared to significant increases seen in 14 control subjects (0.37 L seated <i>versus</i> 0.44 L supine; p<0.001). In COPD, worse dynamic elastance (<i>X</i> _rs5 r_s 0.499; p=0.001) and EFL (Δ<i>X</i> _rs5 r_s -0.413; p=0.007), along with increased age and lower body-mass-index were predictors of supine hyperinflation.</p><p><strong>Conclusion: </strong>Supine persistent hyperinflation occurs in COPD and is associated with increased dynamic elastance and EFL, likely the result of increased airway closure due to gravitational redistribution of lung mass.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}